Research material and lot documents.
BPC-157 peptide for sale appears under several names, forms and label amounts, so a listing needs to be read against the identity records. Curo's recovery and regenerative research catalog lists a BPC-157 5mg vial.
The catalog lists BPC-157 5mg as one vial and a BPC-157 and TB-500 set as two separately packaged vials. Lot reports are grouped by lot number in Curo's lot certificate library. The testing standard page describes the report fields. These are supplier statements, and a listing or a standard does not prove what is in a given vial.
FDA's briefing document dated May 11, 2026 gives these reference entries:
BPC-157 (free base): UNII 8ED8NXK95P, CAS 137525-51-0, formula C62H98N16O22, molecular weight 1419.5.
BPC-157 acetate: UNII PAR2FC72XP, CAS 216441-37-1, formula C62H98N16O22 with X molecules of acetic acid (C2H4O2).
Source: FDA briefing document, Table 1. FDA also looked at the two nomination packages it received. Their certificates of analysis were for BPC-157 acetate, while the CAS number, formula and molecular weight on the certificates matched the free base. FDA wrote that "the nominated BDS is not consistent with what is listed in the Certificate of Analysis (CoA)." Here BDS means bulk drug substance. A listing, a CAS number and a certificate each have to name the same form.
The testing page lists identity by FTIR or LC-MS, purity by HPLC as a percent of peak area, fill in mg per vial, and endotoxin and sterility where available. It defines identity as confirmation that the sample is the expected compound and purity as the target compound's share of the total detected peak area, so the two fields answer different questions. Source: Curo's testing standard page.
For BPC-157 acetate, FDA wrote that both nomination packages included certificates with results for appearance, identification, purity, solubility, related substances (unspecified impurity) and acetic acid content, and that "There were no testing results for the quality control attributes on specified impurities, aggregates, bioburden load (microbial enumeration test) and/or bacterial endotoxin levels." Source: FDA briefing document, section II.A.2.
A certificate describes the lot it names. It does not describe another lot, and it does not record how a person responds to the material. FDA's briefing document concludes: "There is insufficient clinical safety information to characterize the safety profile of BPC-157 (free base) and BPC-157 acetate." Source: FDA briefing document, section II.D.
A researcher can start with the catalog and the lot library linked above, then match the listing to the lot report as described on this page. A listing gives a name and a label amount. The lot report is the record of the lot.
No. By the definitions on Curo's testing standard page, purity is the target compound's share of the detected peak area, and identity is the field that confirms the compound.
It is the labeled amount of material in a vial. The fill field of a lot report records the measured amount per vial.
Curo's research-use policy designates its products as research use only and says they are not intended for human or animal consumption or for diagnostic or therapeutic use. The BPC-157 FDA status page quotes FDA's statements about BPC-157, and it does not give a legal conclusion.
The BPC-157 research page lists the studies by model and the registry records. The BPC-157 identity page gives the names and identifiers.